

ASX Release
27 December 2023

ASX Code: MEM

EXTENSION OF PRO-RATA NON-RENOUNCEABLE ENTITLEMENT ISSUE

Memphasys Limited (ASX: MEM) (the “Company”) refers to the pro-rata non-renounceable entitlement offer (**Offer**) dated 4 December 2023 and that was despatched to shareholders on 13 December 2023.

The Offer is for two (2) fully paid ordinary shares (Share) for every nine (9) Shares held by those eligible shareholders registered at the record date of Friday 8 December 2023 (Record Date) at an issue price of \$0.01 per Share (Offer) together with one (1) free New Option for every two (2) Shares applied for and issued, to raise up to approximately \$2,132,268.

The Company advises that it has extended the closing date of the Offer, that will now close on Monday, 9 January 2024.

The new timetable is as follows:

Closing Date as at 5:00pm AEDT*	9 January 2024
Shares quoted on a deferred settlement basis	10 January 2024
ASX and Underwriter notified of under subscriptions	12 January 2024
Underwriter subscribes for Shortfall under terms of Underwriting Agreement	16 January 2024
Issue date and lodgement of Appendix 2A with ASX applying for quotation of the Shares (before noon, Sydney time)	16 January 2024
Quotation of Shares issued under the Entitlement Offer*	17 January 2024
General Meeting of the Company	early February 2024
Issue date of New Options under the Placement Options offer	early February 2024

* The Directors may extend the Closing Date by giving at least 3 Business Days ‘notice to ASX prior to the Closing Date. Accordingly, the date the Shares are expected to commence trading on ASX may vary.

This release is authorised by the Board of Directors of Memphasys Limited.

For further information please contact:

Mr Andrew Metcalfe

Company Secretary

E: info@memphasys.com P: +61 2 8415 7300

About Memphasys:

Memphasys Limited (ASX: MEM) specialises in biological separations and reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, *in vitro* diagnostics, and new proprietary media. The Company’s patented bio-separation technology, utilised by the Company’s most advanced product, the Felix™ device, combines electrophoresis with proprietary size exclusion membranes to separate sperm cells for human artificial reproduction. Website: www.memphasys.com